Celgene Corporation (CELG)
(Delayed Data from NSDQ)
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Valeant (VRX) Tops Q4 Earnings, Shares Down on Tepid View
by Zacks Equity Research
Valeant's (VRX) fourth-quarter results beat expectations but the guidance of 2017 was disappointing.
Jazz Pharma (JAZZ) Q4 Earnings Beat, Sales Miss Estimates
by Zacks Equity Research
Jazz Pharmaceuticals Public Limited Company (JAZZ) reported fourth-quarter 2016 earnings of $1.91 per share which beat the Zacks Consensus Estimate of $1.65.
Kite Pharma (KITE) Posts Q4 Loss; Up on Positive Cancer Data
by Zacks Equity Research
Kite Pharma, Inc. (KITE) reported narrower-than-expected loss in the fourth quarter of 2016.
Medicines Company (MDCO) Q4 Loss Narrower than Expected
by Zacks Equity Research
The Medicines (MDCO) reported a loss of $1.29 per share (including the impact of share-based compensation expenses) in the fourth quarter of 2016, narrower than Zacks Consensus Estimate of a loss of $1.43.
Why Is Celgene (CELG) Up 6% Since the Last Earnings Report?
by Zacks Equity Research
Celgene (CELG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals
by Arpita Dutt
Key updates this week include earnings results from companies like BioMarin and positive data on Kite's (KITE) lead pipeline candidate.
M&As, Pipeline Catalysts to Drive Pharma Sector
by Arpita Dutt
The sector's fundamentals remain strong -- innovation, mergers and acquisitions (M&As), product approvals and positive data flow should act as catalysts.
Endo (ENDP) Beats on Q4 Earnings, Revenues; Guides Low
by Zacks Equity Research
Endo's (ENDP) Q4 results beat expectations but the outlook for 2017 was disappointing and lagged expectations
Horizon (HZNP) Misses on Earnings in Q4, View Disappoints
by Zacks Equity Research
Horizon Pharma's (HZNP) fourth quarter results were disappointing with the company missing on both top- and bottom line estimates. Moreover, the guidance for 2017 also fell short of expectations.
Theravance (TBPH) Q4 Loss Wider than Expected, Revenues Beat
by Zacks Equity Research
Theravance Biopharma, Inc. (TBPH) reported fourth-quarter 2016 loss of $1.36 per share, much wider than both the Zacks Consensus Estimate of a loss of $1.07 and the year-ago loss of $1.23.
Perrigo to Sell Tysabri Royalties; Issues Tepid 2017 View
by Zacks Equity Research
The company also announced that it has signed an agreement to divest the royalties it receives in multiple sclerosis drug, Tysabri, in order to monetize the asset.
Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss
by Zacks Equity Research
Shares of Achillion Pharmaceuticals, Inc. (ACHN) lost almost 9% on Feb 24, 2017, in spite of the company reporting narrower-than-expected fourth-quarter loss a day before.
Intercept (ICPT) Q4 Loss Wider than Expected, Revenues Beat
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $4.84 per share in the fourth quarter of 2016, wider than the Zacks Consensus Estimate of a loss of $3.58.
Emergent (EBS) Beats Earnings, Revenue Estimates in Q4
by Zacks Equity Research
Emergent BioSolutions, Inc. (EBS) reported earnings of 74 cents per share in the fourth quarter of 2016, which surpassed the Zacks Consensus Estimate of 60 cents. However, the reported figure decreased from 77 cents earned in the year-ago period.
BioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) reported a loss of 37 cents per share in the fourth quarter of 2016.
Juno Therapeutics (JUNO) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Juno Therapeutics Inc. (JUNO) is set to report fourth-quarter 2016 results on Mar 1, after the market closes.
Forget Alexion, Buy these 4 Biotech Stocks Instead
by Arpita Dutt
We advise investors to consider biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.
Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up
by Zacks Equity Research
Agios Pharmaceuticals, Inc. (AGIO) posted fourth-quarter 2016 loss of $1.34 per share, narrower than the Zacks Consensus Estimate of a loss of $1.55 but wider than the year-ago loss of $1.08.
Amgen Looking to Broaden Leukemia Drug Blincyto's Label
by Zacks Equity Research
Biotech major Amgen Inc. (AMGN) announced that it has submitted a supplemental biologics license application (sBLA) to the FDA for its leukemia immunotherapy Blincyto.
Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data
by Arpita Dutt
Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process.
The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics
Forget Gilead, Buy These 5 Biotech Stocks Instead
by Arpita Dutt
With Gilead (GILD) providing a not-so-rosy outlook for 2017 as its HCV franchise continues to face challenges, here's a look at 5 biotech stocks that look better-positioned.
The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals
The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma
5 Great Biotech Stocks to Buy Now
by Swarup Gupta
Biotechs have stabilized and still offer the potential to deliver substantial returns.